Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy

To the Editor The study conducted by Hathaway et al demonstrated a potential association between the use of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide for both diabetes and weight management and an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION). The authors are to be commended for a well-conducted study and in particular for the added rigor of a manual record review to confirm diagnoses of NAION in all cases.

This post was originally published on this site